NextTrial AI
With NextTrial AI’s unified data repository, integrated AI and self-service analytics, companies can take control of data and achieve quality outcomes faster.
BRIDGEWATER, N.J. (PRWEB)
March 02, 2022
NextTrial AI has launched a collaborative, artificial intelligence-powered smart data platform to help expedite clinical trial research and enable faster access to innovative medicines. The NextTrial AI platform, which will be showcased at the DIA 2022 Global Annual Meeting in Chicago in June, is a data-rich business process-enabled environment that empowers study teams to make informed decisions at every stage of the clinical trial lifecycle – from translational research, study design, site selection and study conduct to patient engagement and data submission in a regulatory compliant environment.
Data accessibility and information processing present huge challenges in all aspects of clinical trial design and implementation. NextTrial AI provides an innovative solution to overcome these challenges by tapping into human and artificial intelligence to generate quality results faster with greater confidence. The study teams can leverage the unique cloud-based platform primed with a unified data repository to embed use case-oriented predictive analytics and AI routines. This can be utilized for a variety of purposes including complex research, intelligent process automation, smart recommendations and to solve data analysis problems. Ultimately, this will support an increase in efficiency, knowledge and oversight to improve data quality and enhance patient outcomes. Sources of data include trial registries, biomarkers, publications, safety, regulatory, RWD and others in addition to data from in-house systems such as IRT, EDC, CTM, eCOA and mHealth.
“Data silos present a significant challenge to all aspects of research and, while actions have been taken to simplify data integration between systems, NextTrial AI goes a step further in extracting the maximum benefit from collected data. The platform not only streamlines access to data from clinically relevant sources but also enriches the raw, aggregated data with AI-derived actionable insights to support confident decision-making throughout the trial lifecycle,” says NextTrial AI founder and CEO Sharad Prakash. “AI has the potential to act as a key player in supporting data-driven clinical outcomes, but it is not a simple quick fix. With the design of NextTrial AI, our goal has been to enable the democratization of data and AI by providing a simple, easy-to-use set of tools that will improve efficiency and subsequently enhance clinical outcomes for patients.”
Prakash previously founded Medsight Solutions, a provider of cloud-based decision analytics software for the life sciences industry, which was acquired by ArisGlobal in Feb 2015. The Medsight software enables biopharmaceutical and regulatory agencies to identify, manage and communicate the medicinal product’s safety risks for end-to-end signal detection and risk management.
“With NextTrial AI’s unified data repository, integrated AI and self-service analytics, companies can take control of data and achieve quality outcomes faster,” Prakash says. “We are excited to showcase our innovation at DIA 2022 to better support the life sciences community by revolutionizing and accelerating the process of bringing novel treatments from bench to bedside. Join us in Chicago from June 19 to 23, 2022.”
About NextTrial AI
NextTrial AI offers a collaborative, AI-powered, cloud-based smart data platform with the goal of accelerating clinical trial research and bringing innovative medicines to patients faster. It achieves this by putting relevant, process-oriented, insight-rich data in the hands of sponsors, CROs, research sites, physicians and other stakeholders for critical scientific research, improving operational efficiency, informed decision making and gaining complete trial oversight from inception to commercialization. NextTrial AI is headquartered in New Jersey, USA with an office in Bengaluru, India. For more updates follow us on LinkedIn and Twitter.
Share article on social media or email: